Karl Gaffney

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Ankylosing Spondylitis

Top Venues

Rheumatology advances in practice

Annals of the rheumatic diseases

Expert opinion on biological therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Maureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, Karl Gaffney, Lianne S Gensler, Christine de la Loge, Thomas Vaux, Carmen Fleurinck, Ute Massow, Vanessa Taieb, Michael F Mørup, Atul Deodhar, Martin Rudwaleit
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD open 10 (2) (2024)
Maureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, Karl Gaffney, Lianne S Gensler, Christine de la Loge, Thomas Vaux, Carmen Fleurinck, Ute Massow, Vanessa Taieb, Michael F Mørup, Atul Deodhar, Martin Rudwaleit
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD open 10 (2) (2024)
Jake Weddell, Stephanie Rose Harrison, Alexander N Bennett, Karl Gaffney, Gareth T Jones, Pedro M Machado, Jonathan Packham, Alice Heaney, Sizheng Steven Zhao, Stefan Siebert, Helena Marzo-Ortega
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis. Rheumatology advances in practice 8 (3) (2024)
Jake Weddell, Stephanie Rose Harrison, Alexander N Bennett, Karl Gaffney, Gareth T Jones, Pedro M Machado, Jonathan Packham, Alice Heaney, Sizheng Steven Zhao, Stefan Siebert, Helena Marzo-Ortega
British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis. Rheumatology advances in practice 8 (3) (2024)
Maureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, Karl Gaffney, Lianne S Gensler, Christine de la Loge, Thomas Vaux, Carmen Fleurinck, Ute Massow, Vanessa Taieb, Michael F Mørup, Atul Deodhar, Martin Rudwaleit
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD open 10 (2) (2024)
Maureen Dubreuil, Victoria Navarro-Compán, Annelies Boonen, Karl Gaffney, Lianne S Gensler, Christine de la Loge, Thomas Vaux, Carmen Fleurinck, Ute Massow, Vanessa Taieb, Michael F Mørup, Atul Deodhar, Martin Rudwaleit
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD open 10 (2) (2024)
Désirée Mfm van der Heijde, Atul A Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip E Van den Bosch, Thomas Vaux, Huji Xu
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the rheumatic diseases (2023)
Karl Gaffney, Nicola Gullick, Kirsten MacKay, Yusuf Patel, Alice Heaney, Tom Sheeran, Louise Hemmings, Paula Pamies
Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Rheumatology advances in practice 7 (3) (2023)
Sizheng Steven Zhao, Stephanie R Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J Gregory, Gareth T Jones, Helena Marzo-Ortega, Daniel J Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology advances in practice 7 (2) (2023)
Désirée Mfm van der Heijde, Atul A Deodhar, Xenofon Baraliakos, Matthew A Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, Alicia M Ellis, Carmen Fleurinck, Karl Gaffney, Lianne S Gensler, Nigil Haroon, Marina Magrey, Walter P Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martin Rudwaleit, Julie Shepherd-Smith, Tetsuya Tomita, Filip E Van den Bosch, Thomas Vaux, Huji Xu
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the rheumatic diseases (2023)
Sizheng Steven Zhao, Stephanie R Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J Gregory, Gareth T Jones, Helena Marzo-Ortega, Daniel J Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology advances in practice 7 (2) (2023)
Mohammad H Derakhshan, Linda E Dean, Gareth T Jones, Stefan Siebert, Karl Gaffney
Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis. RMD open 6 (2) (2021)
Francisco Javier García-Alonso, Karl Gaffney, David Young, Hans C Ebbers, Giampiero Girolomoni
Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi TM ): a multidisciplinary perspective. Expert opinion on biological therapy 22 (2) (2021)